KSQ Therapeutics Begins Clinical Trials with Initial Patient Dosed for CRISPR/Cas9 Modified eTIL® Therapy KSQ-001EX.

Avidity Reveals Remarkable Phase 1/2 FORTITUDE™ Trial Results for AOC 1020 Showing Over 50% Decrease in DUX4 Genes and Functional Improvement Trends in Facioscapulohumeral Muscular Dystrophy Patients.

Zumutor Biologics Inc. has recently disclosed that the initial patient has been treated in its Phase 1 clinical trial with ZM008.

Nektar Therapeutics Unveils Initial Preclinical Findings on NKTR-0165, a TNFR2 Agonist Antibody for Inflammatory Disease Therapy, at EULAR 2024.

Vivani Medical Reports FDA Approval of New Drug Application and Removal of Clinical Hold for NPM-119, a Mini Subdermal GLP-1 Implant.

The FDA has approved Kevzara® (sarilumab) for treating active polyarticular juvenile idiopathic arthritis (pJIA).

Ipsen's Iqirvo® gets expedited U.S. FDA approval as an innovative PPAR therapy for primary biliary cholangitis.

Jun 14th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

NMD Pharma A/S announced today that it has administered the first dose to a patient with generalized myasthenia gravis in a Phase 2b clinical trial of NMD670.

Alvotech and STADA are expanding their joint efforts to include AVT03, a biosimilar candidate in clinical development that uses Prolia/Xgeva (denosumab) as reference drugs aimed at treating osteoporosis and cancer-induced bone deterioration.

Assembly Biosciences, has reported that the initial participant has received a dose in the Phase 1a/b clinical trial of its long-acting herpes simplex virus helicase-primase inhibitor, ABI-5366.

Entos Pharmaceuticals have announced that Entos has secured authorization from Health Canada to commence a phase 1/2 clinical study assessing Covigenix VAX-002.